Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy

• Xianwu Wang,
• Shuyao Lang,
• Yunpeng Tian,
• Jianghong Zhang,
• Xu Yan,
• Zhihong Fang,
• Jian Weng,
• Na Lu,
• Xuanjun Wu,
• Tianlu Li,
• Hongzhi Cao,
• Zhu Li,
• Xuefei Huang

Affiliations

Xianwu Wang

Department of Biomaterials, College of Materials, Xiamen University, Xiamen, P. R. China

Shuyao Lang

Departments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan, United States

Yunpeng Tian

Xiamen Nuokangde Biological Technology Co., Ltd., Xiamen, China

Jianghong Zhang

Xiamen Nuokangde Biological Technology Co., Ltd., Xiamen, China

Xu Yan

School of Chemistry, Sun Yat-Sen University, Guangzhou, China

Zhihong Fang

Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China

Jian Weng

Department of Biomaterials, College of Materials, Xiamen University, Xiamen, P. R. China

Na Lu

National Glycoengineering Research Center, Shandong University, Qingdao, Shandong, China

Xuanjun Wu

Departments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan, United States

Tianlu Li

Departments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan, United States

Hongzhi Cao

National Glycoengineering Research Center, Shandong University, Qingdao, Shandong, China

Zhu Li

Xiamen Nuokangde Biological Technology Co., Ltd., Xiamen, China

Xuefei Huang

Departments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan, United States